New pill could ease carcinoid syndrome Flare-Ups
NCT ID NCT05361668
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 2 trial tested paltusotine, an oral drug, in 36 adults with carcinoid syndrome. The study looked at safety and how the body processes the drug at different doses. Participants were randomly assigned to 40 mg or 80 mg daily, with dose adjustments allowed. The goal is to find a convenient pill option to manage symptoms like diarrhea and flushing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- paltusotine
- What this could lead to
- If successful, paltusotine could offer a new oral option to control symptoms like diarrhea and flushing in people with carcinoid syndrome.
- What could go wrong
- This is an early Phase 2 trial with only 36 participants. The drug may not prove effective or safe in larger studies, and side effects are still being evaluated.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Crinetics Study Site
Los Angeles, California, 90048, United States
-
Crinetics Study Site
Los Angeles, California, 90095, United States
-
Crinetics Study Site
Newport Beach, California, 92663, United States
-
Crinetics Study Site
Stanford, California, 94305, United States
-
Crinetics Study Site
Miami, Florida, 33136, United States
-
Crinetics Study Site
Iowa City, Iowa, 52242, United States
-
Crinetics Study Site
Lexington, Kentucky, 40506, United States
-
Crinetics Study Site
New Orleans, Louisiana, 70112, United States
-
Crinetics Study Site
Boston, Massachusetts, 02118, United States
-
Crinetics Study Site
Rochester, Minnesota, 55905, United States
-
Crinetics Study Site
New York, New York, 10029, United States
-
Crinetics Study Site
Stony Brook, New York, 11794, United States
-
Crinetics Study Site
Cleveland, Ohio, 44106, United States
-
Crinetics Study Site
Columbus, Ohio, 43210, United States
-
Crinetics Study Site
Houston, Texas, 77030, United States
-
Crinetics Study Site
CABA, Buenos Aires, C1180 AAX, Argentina
-
Crinetics Study Site
CABA, Buenos Aires, C1264AAA, Argentina
-
Crinetics Study Site
CABA, Buenos Aires, C1426ANZ, Argentina
-
Crinetics Study Site
CABA, C1017AAS, Argentina
-
Crinetics Study Site
CABA, C1425BGH, Argentina
-
Crinetics Study Site
Fortaleza, Ceará, 60430-275, Brazil
-
Crinetics Study Site
Rio de Janeiro, Rio de Janeiro, 20231-092, Brazil
-
Crinetics Study Site
Rio de Janeiro, Rio de Janeiro, 22281-100, Brazil
-
Crinetics Study Site
Criciúma, Santa Catarina, 88811508, Brazil
-
Crinetics Study Site
São Paulo, São Paulo, 01509-010, Brazil
-
Crinetics Study Site
Rio de Janeiro, 22061-080, Brazil
-
Crinetics Study Site
Toronto, M4N 3M5, Canada
-
Crinetics Study Site
Mexico City, Cuauhtemoc, 06100, Mexico
-
Crinetics Study Site
Querétaro City, Querétaro, 76000, Mexico
-
Crinetics Study Site
Querétaro City, Querétaro, 76070, Mexico
-
Crinetics Study Site
Katowice, 40-514, Poland
-
Crinetics Study Site
Warsaw, 02-351, Poland
-
Crinetics Study Site
Wroclaw, 53-413, Poland
-
Crinetics Study Site Peru #1
Lima, 15036, Peru
-
Crinetics Study Site Peru #2
Lima, 15036, Peru
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Two-Drug combo aims to stall rare gut tumors
- New scan could spot hidden tumors more accurately
- New valve implant offers hope for rare heart condition
- New registry aims to unlock secrets of rare heart disease from gut tumors
- New CT technique may spot Hard-to-Find gut tumors
- New hope for rare tumors: tarlatamab trial opens